---
title: A Phase III Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia
nct_id: NCT03674008
overall_status: COMPLETED
phase: PHASE3
sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd
study_type: INTERVENTIONAL
primary_condition: Sedation or Anesthesia
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03674008.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03674008"
ct_last_update_post_date: 2019-07-05
last_seen_at: "2026-05-12T06:00:59.514Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Phase III Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia

**Official Title:** A Phase III,Randomized, Double-blind, Propofol-controlled, Parallel-design, Multi-center Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia in Patients Undergoing Colonoscopy and Gastroscopy

**NCT ID:** [NCT03674008](https://clinicaltrials.gov/study/NCT03674008)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 280
- **Lead Sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Conditions:** Sedation or Anesthesia
- **Start Date:** 2018-10-09
- **Completion Date:** 2019-03-10
- **CT.gov Last Update:** 2019-07-05

## Brief Summary

This is a Phase III, randomized, double-blind, propofol-controlled, parallel-design, multi-center study to evaluate the efficacy and safety of HSK3486 for sedation or anesthesia in patients undergoing colonoscopy and gastroscopy.

The study will enroll approximately 280 adults. The maximum study duration is anticipated to be up to nine months.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Scheduled to undergo a diagnostic or therapeutic colonoscopy or gastroscopy;
2. Male or female patients, ASA grade I\~II, aged ≥ 18 and \< 65;
3. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;
4. During screening and baseline, the respiratory rate ≥10 and ≤24, SpO2 when inhaling ≥95%, SBP≥90mmHg, DBP≥60mmHg, HR≥60 and ≤100;
5. Patient can understand the procedure of this study and is willing to comply with study requirements. The patient can sign the ICF voluntarily.

Exclusion Criteria:

1. Patients were contraindicated in general anesthesia.
2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products or a medical condition such that these agents were contraindicated.
3. The patient has some history or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period.
4. Patients with a history of drug or ethanol abuse with the past 3 months.
5. Patients with respiratory management difficulties (Modified Mallampati grade IV).
6. Patients in receipt of any investigational drug within 30 days before screening.
7. Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics within 72 hours prior to baseline.
8. Abnormal laboratory results consisting of any of the following:

1\) neutrophil count≤ 1.5×109/L； 2）platelet≤ 80×109/L； 3）hemoglobin≤ 90 g/L; 4）aspartate aminotransferase≥ 1.5×ULN； 5）total bilirubin≥ 1.5×ULN； 6） serum creatinine≥ 1.2×ULN. 9. Pregnant women or female patients with a positive serum or urine human chorionic gonadotropin pregnancy test at screening or baseline or lactating female patients.

10\. Patients with an inability to communicate well with the investigator, or deemed unsuitable according to the investigator (in each case providing a reason).
```

## Arms

- **HSK3486** (EXPERIMENTAL) — 0.4mg/kg/0.2 mg/kg
- **Propofol** (ACTIVE_COMPARATOR) — 1.5mg/kg/0.75mg/kg

## Interventions

- **HSK3486** (DRUG) — HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
- **Propofol** (DRUG) — Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.

## Primary Outcomes

- **Success of colonoscopy procedure** _(time frame: from the first dose of the study drug to removal of colonoscope on day 1)_ — Measured by completion of colonoscopy, no requirement for an alternative sedative or anesthesia drug and no requirement for more than 5 doses of study drug within any 15 minute period.

## Secondary Outcomes

- **The success rate of the gastroscopy procedure** _(time frame: from the first dose of the study drug to removal of gastroscope on day 1)_
- **The success rate of the colonoscopy and gastroscopy procedure** _(time frame: from the first dose of the study drug to rem oval of colonoscope and gastroscope on day 1)_
- **Time to induction of sedation or anaesthesia** _(time frame: from the first dose of the study drug to the first MOAA/S scores≤1 on day 1)_
- **Time to start of procedure** _(time frame: From first dose of study drug until insertion of colonoscope or gastroscope on day 1)_
- **Time to fully alert** _(time frame: from the removal of colonoscopy or gastroscopy procedure, until the first of three consecutive MOAA/S scores of 5 on day 1)_
- **Time to discharge** _(time frame: from the removal of colonoscopy or gastroscopy procedure, until the first of three consecutive Aldrete scores of more than or equal to 9 on day 1)_
- **Sedation/anesthesia satisfaction, satisfaction assessment of subjects, anesthesiologists, and endoscopic physicians** _(time frame: from time to fully alert, until time to discharge on day 1)_

## Locations (1)

- West China Hospital, Sichuan University, Changde, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.west china hospital, sichuan university|changde||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03674008.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03674008*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*